Bibliothek

feed icon rss

Ihre E-Mail wurde erfolgreich gesendet. Bitte prüfen Sie Ihren Maileingang.

Leider ist ein Fehler beim E-Mail-Versand aufgetreten. Bitte versuchen Sie es erneut.

Vorgang fortführen?

Exportieren
  • 1
    Digitale Medien
    Digitale Medien
    Springer
    Journal of assisted reproduction and genetics 10 (1993), S. 130-136 
    ISSN: 1573-7330
    Schlagwort(e): follicle stimulating hormone ; luteinizing hormone ; estradiol ; oocytes
    Quelle: Springer Online Journal Archives 1860-2000
    Thema: Medizin
    Beschreibung / Inhaltsverzeichnis: Methods One hundred eleven consecutive females with infertility due to various etiologies were investigated. Cycle day 3 serum levels of FSH, LH, and E2 were determined prior to ovulation induction with a combination of clomiphene citrate and human gonadotropins. Follicular growth was monitored ultrasonically, and when appropriate, oocytes were recruited, counted, graded, and then used, as prearranged, for either IVF or GIFT. Basal hormone levels were compared to the peak E2 concentration, the number of follicles aspirated, and the number of preovulatory oocytes recovered following drug therapy. Details of resulting pregnancies were also recorded.
    Kurzfassung: Results Patients with low basal FSH levels (〈11.5 mIu/ml) yielded a higher mean number of preovulatory oocytes than those with high values (〉11.5 mIu/ml), i.e., 6.7 oocytes per cycle vs 2.5 oocytes (P 〈 0.001). In the low group 97% of cycles yielded more than three fertilizable oocytes compared to 42% in the high group (P 〈 0.5). There were 16 term pregnancies (16%) in the low group and 1 (8.3%) in the high group. Basal LH and E2 levels did not improve on the ability to distinguish between different populations of infertile females who responded differently to ovulation induction.
    Notizen: Aim To determine the value of basal follicle stimulating hormone (FSH), luteinizing hormone (LH), and estradiol (E2) levels on cycle day 3 in predicting the ovulation stimulation response in patients receiving exogenous gonadotropins for in vitro fertilization (IVF) or gamete intrafallopian transfer (GIFT).
    Materialart: Digitale Medien
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 2
    ISSN: 1573-7330
    Schlagwort(e): assisted reproduction ; gonadotropin releasing hormone (GnRHa) ; gamete intrafallopian transfer (GIFT) ; human menopausal gonadotropin (hMG) ; in vitro fertilization (IVF) ; clomiphene citrate ; contraceptive pill ; ovulation induction
    Quelle: Springer Online Journal Archives 1860-2000
    Thema: Medizin
    Beschreibung / Inhaltsverzeichnis: Results The overall pregnancy rate was 21.6% (11/51) in the study group and 47% (24/51) in the control group (P =0.01). However, the ongoing pregnancy rate in the two groups did not differ significantly, 11.8% (6/51) vs 27.5% (14/51) (P =0.08). In the study group, 7.8% of patients had to be seen over a weekend, compared to 13.7% in the control group (not significant).
    Kurzfassung: Conclusion From the findings we conclude that, although this method of controlling cycles can be useful in selected patients, it is not the ultimate method.
    Notizen: Purpose It may sometimes be necessary to regulate cycles in assisted reproduction. Cycles can be regulated with gonadotropin releasing hormone (GnRHa) agonist but other methods can also be used. The aim of this study was to compare the pregnancy rate in a gamete intrafallopian transfer (GIFT) program in patients receiving a contraceptive pill/Clomid/human menopausal gonadotropin (hMG) regimen (study group), with the standard Clomid/hMG regime (control group). Fifty one patients in the study group were carefully matched for patient age, infertility diagnosis (female), semen parameters, number of follicles, and number of oocytes transferred into consideration with a control group.
    Materialart: Digitale Medien
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
Schließen ⊗
Diese Webseite nutzt Cookies und das Analyse-Tool Matomo. Weitere Informationen finden Sie hier...